2024
Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3Lymphoma
2023
Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma
Olszewski A, Ollila T, Pelcovits A, Chorzalska A, Morgan J, McMahon J, Donnelly S, Huntington S, Matasar M, Reagan J, Milrod C, Dubielecka P. Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma. Blood 2023, 142: 1651. DOI: 10.1182/blood-2023-181418.Peer-Reviewed Original ResearchEnd of therapyCytokine release syndromeMarginal zone lymphomaT cellsComplete responsePD1 expressionNK cellsB cellsEffector memory T cellsCheckpoint inhibitor combinationsExpression of LAG3Immune cell changesB-cell depletionFirst-line therapyExpansion of TregsT cell exhaustionMemory T cellsPrior chemotherapy exposureImmune cell subsetsImmune cell compositionPeripheral blood samplesMulticolor flow cytometrySignificant increaseTreatment-induced changesExhausted phenotypeCost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapyQuality-adjusted life yearsIncremental cost-effectiveness ratioCAR T cellsChimeric antigen receptor T-cell therapySOC therapyFollicular lymphomaT cellsLife yearsR FLRefractory follicular lymphomaT cell strategiesThird-line settingLines of therapyIncremental clinical benefitUS payer perspectiveCost-effectiveness ratioTherapy remissionUnselected patientsCare therapyClinical benefitClinical trialsTreatment strategiesPayer perspective
2019
AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study
Huntington S, Kallam A, Basile F, Ulanet D, Xu H, Yin F, Mobilia M, Cooper M, Shah B, Leonard J, von Keudell G, Gopal A. AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study. Blood 2019, 134: 1286. DOI: 10.1182/blood-2019-123420.Peer-Reviewed Original ResearchDose-limiting toxicityDiffuse large B-cellDose-escalation phaseAgios PharmaceuticalsAdvanced lymphomaHematologic malignanciesKaryopharm TherapeuticsSeattle GeneticsEscalation phaseT cellsEastern Cooperative Oncology Group performance statusADC therapeuticsActive central nervous system diseaseAdaptive Bayesian logistic regression modelChimeric antigen receptor T-cell therapyPrior stem cell transplantSerum total bilirubin levelPhase 1 clinical studyCentral nervous system diseaseDose-expansion phaseOptimal starting doseCycles of therapyOpen-label studyAbsolute neutrophil countAdvanced solid tumors
2015
Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells
Evans AG, Rothberg PG, Burack WR, Huntington SF, Porter DL, Friedberg JW, Liesveld JL. Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells. British Journal Of Haematology 2015, 171: 205-209. PMID: 26084925, DOI: 10.1111/bjh.13562.Peer-Reviewed Original ResearchT cellsChimeric antigen receptor T cellsRefractory chronic lymphocytic leukemiaAntigen receptor T cellsCAR T-cell therapyPre-plasma cellsReceptor T cellsChimeric antigen receptorChronic lymphocytic leukemiaMolecular genetic evaluationPlasmablastic lymphomaRichter transformationMature lymphomasRoutine markersLymphocytic leukemiaSingle patientNormal cellular counterpartsCell therapyAntigen receptorLymphoid differentiationCD19PatientsLymphomaCellsCellular counterparts